Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes.

@article{Kondo2008ModificationOH,
  title={Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes.},
  author={Kazunari Kondo and Hiroyuki Ochi and Tamae Matsumoto and Hiroyuki Yoshikawa and Tadahito Kanda},
  journal={Journal of medical virology},
  year={2008},
  volume={80 5},
  pages={
          841-6
        }
}
Infection with human papillomavirus 16 (HPV16), which is one of the 15 types of HPV causally associated with cervical cancer and accounts for 50% of the cases, can be prevented in a type-specific manner by an HPV16 virus-like particle (VLP) vaccine comprised of particles of the L1 protein alone. We attempted to modify the VLP vaccine by inserting the HPV16 L2-peptides including cross-neutralization epitopes into the L1 polypeptide. The chimeric L1 had, between L1 amino acids (aa) 430 and 433… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 28 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 24 REFERENCES

ShahKV,Meijer CJLM.2004. Againstwhich human papillomavirus types shall we vaccinate and screen

N Munoz, FX Bosch, +3 authors D Hammouda
  • Int J Cancer 111:278–285
  • 2004
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

HPV Vaccine Study Group

DM Harper, DM Franco, +7 authors G Dubin
  • 2006
VIEW 1 EXCERPT

Heterologouspapillomavirus virus - like particles and human papillomavirus virus - like particle immune complexes activate human Langerhans cells

DaSilvaDM FauschSC, KastWM
  • Vaccine
  • 2005